K2M Group Holdings Inc (NASDAQ:KTWO) has received a consensus rating of “Buy” from the fourteen analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $24.44.
A number of analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of K2M Group from a “sell” rating to a “hold” rating in a research note on Thursday, January 25th. BidaskClub raised shares of K2M Group from a “hold” rating to a “buy” rating in a report on Wednesday, January 10th. Barclays reissued a “buy” rating and set a $25.00 price target on shares of K2M Group in a report on Tuesday, January 9th. Needham & Company LLC boosted their price target on shares of K2M Group from $20.00 to $23.00 and gave the company a “buy” rating in a report on Tuesday, January 9th. Finally, Wells Fargo & Co downgraded shares of K2M Group from an “outperform” rating to a “market perform” rating and set a $23.00 price target for the company. in a report on Monday, December 4th.
K2M Group (KTWO) traded down $0.11 on Friday, hitting $20.61. 364,638 shares of the stock were exchanged, compared to its average volume of 290,036. The stock has a market capitalization of $897.77, a price-to-earnings ratio of -21.25 and a beta of 1.47. K2M Group has a 12 month low of $16.44 and a 12 month high of $25.99. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.06 and a quick ratio of 1.67.
A number of institutional investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC grew its stake in K2M Group by 7,765.0% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 4,719 shares of the medical device company’s stock valued at $100,000 after acquiring an additional 4,659 shares in the last quarter. Rockefeller Financial Services Inc. bought a new stake in shares of K2M Group in the 3rd quarter valued at approximately $105,000. Legal & General Group Plc grew its stake in shares of K2M Group by 41.4% in the 2nd quarter. Legal & General Group Plc now owns 9,561 shares of the medical device company’s stock valued at $232,000 after buying an additional 2,798 shares in the last quarter. Trexquant Investment LP bought a new stake in shares of K2M Group in the 3rd quarter valued at approximately $223,000. Finally, Quantbot Technologies LP boosted its position in K2M Group by 275.9% during the third quarter. Quantbot Technologies LP now owns 10,593 shares of the medical device company’s stock worth $224,000 after purchasing an additional 7,775 shares during the period. Hedge funds and other institutional investors own 98.86% of the company’s stock.
K2M Group Company Profile
K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.
Receive News & Ratings for K2M Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group and related companies with MarketBeat.com's FREE daily email newsletter.